Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

Parkinson's Disease Clinical Trial

Official title:

An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03065192
• Other study ID #: PD-1102
• Status: Completed
• Phase: Phase 1
• Start date: May 11, 2017
• Est. completion date: August 10, 2021

Study information

• Verified date: March 2022
• Source: Neurocrine Biosciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.

Description:

Parkinson's disease (PD) is a neurodegenerative disorder involving loss of dopamine producing neurons located in the striatum. Levodopa is the primary treatment used to treat Parkinson's disease, which converts to dopamine by the enzyme (protein) Aromatic L-Amino Acid Decarboxylase (AADC). As PD progresses, the amount of AADC levels in the brain decreases, and in turn, reduces the amount of dopamine that is produced with each dose of levodopa. The primary objective of this study is to evaluate the safety of increasing AADC levels, via gene delivery. The investigational drug, termed VY-AADC-01, will be injected directly into the striatum during a neurosurgical procedure that is performed with real-time MRI imaging to monitor delivery. Participants will continue to take their Parkinson medications, including levodopa while participating in this study. The safety and potential clinical responses to VY-AADC-01 will be assessed by repeated clinical evaluations of Parkinson's disease, treatment review phone calls, cognitive tests, laboratory blood tests, patient reported outcomes scales, patient diaries, collection of adverse events, and neuro-imaging. Clinical evaluations will be performed over a 3 year follow-up period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: August 10, 2021
• Est. primary completion date: August 10, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Diagnosed with idiopathic PD.
• Adequate duration of levodopa therapy.
• Disease duration of at least 5 years or more.
• Modified Hoehn & Yahr Staging with at least 2.5 hours or more in the OFF state.
• Candidate for surgical intervention because of disabling motor complications.
• UPDRS Part III (total score) of at least 25 in the OFF state.
• Unequivocal responsiveness to dopaminergic therapy.
• Stable Parkinson's symptoms and medications for at least 4 weeks prior to screening evaluation.
• Ability to comprehend and sign the informed consent.
• Normal laboratory values prior to surgery.
• Medically and mentally capable of undergoing and complying with the surgical procedure and protocol requirements.
• Ability to travel to study visits alone or able to designate a caregiver.
• Subject agrees to defer any neurological surgery, including deep brain stimulation, until after completing the 12 month study visit (unless recommended by study neurologist).
• Approved by the Eligibility Review Committee.

Exclusion Criteria:

• Atypical or secondary parkinsonism, including but not limited to symptoms believed to be due to trauma, brain tumor, infection, cerebrovascular disease, other neurological disease, or to drugs, chemicals, or toxins.
• Presence of dementia as defined by a Mattis Dementia Rating Scale - Second Edition (MDRS-2) score of less than 130 at screening.
• Presence or history of psychosis, with the exception of mild, benign hallucinations believed in the judgment of the Investigator to be related to Parkinson's medications.
• Presence of severe depression, as indicated by a BDI-II score greater than 28, or a history of a major affective disorder within 5 years of screening evaluation.
• Active suicidal ideation or suicide attempt within 5 years of screening evaluation.
• History of substance abuse within 2 years of screening evaluation.
• Brain imaging abnormalities in the striatum or other regions that would substantially increase risk of surgery.
• Contraindication to MRI and/or gadoteridol.
• Coagulopathy or inability to temporarily stop any anticoagulation or antiplatelet therapy prior to surgery.
• Prior brain surgery including lesioning procedures, deep brain stimulation, infusion therapies or any other brain surgery.
• Prior gene transfer.
• History of stroke, poorly controlled or significant cardiovascular disease, diabetes, or any other acute or chronic medical condition.
• History of malignancy other than treated carcinoma in situ within 3 years of screening evaluation.
• Clinically apparent or laboratory-detected infection.
• Prior or current treatment with any investigational agent within 2 months of screening evaluation.
• Inability to comply with the procedures of the protocol, including completion of paper Parkinson's disease diaries, frequent and prolonged study visits including off medication visits, and travel.
• Chronic immunosuppressive therapy, including chronic steroids, immunotherapy, cytotoxic therapy, and chemotherapy.
• Any serious medical condition or abnormal finding on physical examination or laboratory investigation that would substantially increase the risks of the study procedures.
• Any medical condition that is likely to lead to disability during the course of the study and interfere with or confound study assessments.
• Pregnant and lactating women.
• Male or female with reproductive capacity who is unwilling to use barrier contraception for 6 months after surgery.
• Plans to receive any vaccination within 30 days of surgery.
• Any factors, medical or social, which would likely cause the participant to be unable to follow the study protocol, including geographical inaccessibility.
• Ongoing treatments including neuroleptic medications, apomorphine, or levodopa infusion therapy (Duopa®).
• Plans to participate in any other therapeutic intervention study within 12 months after surgery.

Related Conditions & MeSH terms

• Basal Ganglia Disease
• Basal Ganglia Diseases
• Brain Diseases
• Central Nervous System Diseases
• Disease
• Idiopathic Parkinson's Disease
• Movement Disorders
• Nervous System Diseases
• Neurodegenerative Diseases
• Parkinson Disease
• Parkinson's Disease
• Parkinsonian Disorders

Intervention

Drug:
• VY-AADC01
Single dose, neurosurgically infused, bilaterally into the striatum.

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	Ohio State University (OSU)	Columbus	Ohio
United States	University of Pittsburgh Medical Center (UPMC)	Pittsburgh	Pennsylvania
United States	University of California, San Francisco (UCSF)	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
Neurocrine Biosciences	Voyager Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Grading of adverse Events/Serious Adverse Events (AE's/SAE's)	Grading will be assessed using NCI CTCAE, version 4.03.	Baseline to 3 Years After Gene Transfer
Primary	Magnetic Resonance Imaging (MRI)	Safety of VY-AADC01 will be assessed by any clinically significant abnormalities on MRI scans as compared to Baseline.	Baseline to 3 Years After Gene Transfer
Primary	Routine physical examinations	Safety of VY-AADC01 will be assessed by routine physical examinations.	Baseline to 3 Years After Gene Transfer
Primary	Routine clinical laboratory analysis	Safety of VY-AADC01 will be assessed by routine clinical laboratory analysis.	Baseline to 3 Years After Gene Transfer
Primary	Change in Columbia-Suicide Severity Rating Scale (C-SSRS) results	C-SSRS is a standardized suicidal rating system.	Baseline to 3 Years After Gene Transfer
Secondary	Change in Parkinson's medications	Change in Parkinson's medications compared to Baseline.	Baseline to 3 Years After Gene Transfer
Secondary	Change in motor function using Parkinson Disease Diaries	Diary used to assess changes in PD motor symptoms.	Baseline to 3 Years After Gene Transfer
Secondary	Change in motor function using a Stand-Walk-Sit Test	Standardized test used in PD studies to assess functional mobility.	Baseline to 3 Years After Gene Transfer
Secondary	Change in motor function using Modified Hoehn and Yahr Scale	Scale used to measure overall level of disability due to PD.	Baseline to 3 Years After Gene Transfer
Secondary	Change in motor function using Unified Parkinson's Disease Rating Scale (UPDRS)	Standard assessment scale used to quantify signs and symptoms of PD.	Baseline to 3 Years After Gene Transfer
Secondary	Change in occurrence of dyskinesia using Unified Dyskinesia Rating Scale (UDysRS)	Comprehensive rating tool used to assess essential features of dyskinesia in PD.	Baseline to 3 Years After Gene Transfer
Secondary	Change in mood using Beck Depression Inventory II (BDI-II)	Self-administered measure of depression symptoms.	Baseline to 3 Years After Gene Transfer
Secondary	Change in cognitive function using Modified Cognitive Assessment (MoCA)	Rapid screening instrument for mild cognitive dysfunction.	Baseline to 3 Years After Gene Transfer
Secondary	Change in cognitive function using Mattis Dementia Rating Scale - Second Edition (MDRS-2)	Standardized neuropsychological test battery to measure dementia.	Baseline to 3 Years After Gene Transfer
Secondary	Change in compulsive behavior using the Questionnaire Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)	Rating scale to quantify the severity of a variety of compulsive disorders and behaviors.	Baseline to 3 Years After Gene Transfer
Secondary	Change in sleep quality and disturbance using the Parkinson's Disease Sleep Scale 2 (PDSS-2)	Visual analogue scale addressing 15 commonly reported symptoms associated with sleep disturbance in PD.	Baseline to 3 Years After Gene Transfer
Secondary	Change in Non-Motor System Scale (NMSS)	Standard rating scale that assesses the non-motor symptoms that may be associated with PD.	Baseline to 3 Years Gene Transfer
Secondary	Change in quality of life using Parkinson's Disease Questionnaire (PDQ39)	Validated questionnaire to measure health related quality of life in PD patients.	Baseline to 3 Years After Gene Transfer
Secondary	Change in quality of life using Schwab and England Scale	PD specific disability scale used to express the levels of independence with activities of daily living.	Baseline to 3 Years After Gene Transfer
Secondary	Change in quality of life using in Clinical Global Impression Scale (CGI)	Scale used to assess treatment response in psychiatric patients.	Baseline to 3 Years After Gene Transfer
Secondary	Change in quality of life using Patient Global Impression Scale (PGI)	Scale used to assess participants improvement in their PD symptoms.	Baseline to 3 Years After Gene Transfer

External Links

•   Company Website